AAAAAA
Results: 1-25/44
Authors:
ALS C
LAENG H
CERNY T
KINSER JA
ROSLER H
HAUSLER R
Citation: C. Als et al., PRIMARY CERVICAL MALIGNANT TERATOMA WITH A RIB METASTASIS IN AN ADULT- 5-YEAR SURVIVAL AFTER SURGERY AND CHEMOTHERAPY - A CASE-REPORT WITHA REVIEW OF THE LITERATURE, Annals of oncology, 9(9), 1998, pp. 1015-1022
Authors:
LEYVRAZ S
BACCHI M
CERNY T
LISSONI A
SESSA C
BRESSOUD A
HERMANN R
Citation: S. Leyvraz et al., PHASE-I MULTICENTER STUDY OF COMBINED HIGH-DOSE IFOSFAMIDE AND DOXORUBICIN IN THE TREATMENT OF ADVANCED SARCOMAS, Annals of oncology, 9(8), 1998, pp. 877-884
Authors:
BETTICHER DC
RATSCHILLER D
SCHMITZ SFH
VONROHR A
HESS U
ZULIAN G
WERNLI M
TICHELLI A
TOBLER A
FEY MF
CERNY T
Citation: Dc. Betticher et al., REDUCED DOSE OF SUBCUTANEOUS CLADRIBINE INDUCES IDENTICAL RESPONSE RATES BUT DECREASED TOXICITY IN PRETREATED CHRONIC LYMPHOCYTIC-LEUKEMIA, Annals of oncology, 9(7), 1998, pp. 721-726
Authors:
VANWEGBERG B
BACCHI M
HEUSSER P
HELWIG S
SCHAAD R
VONROHR E
BERNHARD J
HURNY C
CASTIGLIONE M
CERNY T
Citation: B. Vanwegberg et al., THE COGNITIVE-SPIRITUAL DIMENSION - AN IMPORTANT ADDITION TO THE ASSESSMENT OF QUALITY-OF-LIFE - VALIDATION OF A QUESTIONNAIRE (SELT-M) IN PATIENTS WITH ADVANCED CANCER, Annals of oncology, 9(10), 1998, pp. 1091-1096
Authors:
BETTICHER DC
VONROHR A
RATSCHILLER D
SCHMITZ SFH
EGGER T
SONDEREGGER T
HERRMANN R
KRONER T
ZULIAN GB
CAVALLI F
FEY MF
CERNY T
Citation: Dc. Betticher et al., FEWER INFECTIONS, BUT MAINTAINED ANTITUMOR-ACTIVITY WITH LOWER-DOSE VERSUS STANDARD-DOSE CLADRIBINE IN PRETREATED LOW-GRADE NON-HODGKINS-LYMPHOMA, Journal of clinical oncology, 16(3), 1998, pp. 850-858
Authors:
AESCHLIMANN C
KUPFER A
SCHEFER H
CERNY T
Citation: C. Aeschlimann et al., COMPARATIVE PHARMACOKINETICS OF ORAL AND INTRAVENOUS IFOSFAMIDE MESNAMETHYLENE-BLUE THERAPY/, Drug metabolism and disposition, 26(9), 1998, pp. 883-890
Authors:
VISARIUS TM
BAHLER H
KUPFER A
CERNY T
LAUTERBURG BH
Citation: Tm. Visarius et al., THIODIGLYCOLIC ACID IS EXCRETED BY HUMANS RECEIVING IFOSFAMIDE AND INHIBITS MITOCHONDRIAL-FUNCTION IN RATS, Drug metabolism and disposition, 26(3), 1998, pp. 193-196
Authors:
JONCOURT F
BUSER K
ALTERMATT H
BACCHI M
OBERLI A
CERNY T
Citation: F. Joncourt et al., MULTIPLE-DRUG RESISTANCE PARAMETER EXPRESSION IN OVARIAN-CANCER, Gynecologic oncology (Print), 70(2), 1998, pp. 176-182
Authors:
SPERB RA
VONROHR A
RATSCHILLER D
BACCHI M
TICHELLI A
HESS U
CERNY T
TOBLER A
BETTICHER DC
Citation: Ra. Sperb et al., 2-CDA IN THE TREATMENT OF HAIRY-CELL LEUKEMIA - INTRAVENOUS VS SUBCUTANEOUS ADMINISTRATION, Schweizerische medizinische Wochenschrift, 128(42), 1998, pp. 1593-1597
Authors:
FURRER M
LARDINOIS D
THORMANN WG
ALTERMATT HJ
BETTICHER D
CERNY T
FIKRLE A
METTLER D
ALTHAUS U
BURT ME
RIS HB
Citation: M. Furrer et al., ISOLATED LUNG PERFUSION - SINGLE-PASS SYSTEM VERSUS RECIRCULATING BLOOD PERFUSION IN PIGS, The Annals of thoracic surgery, 65(5), 1998, pp. 1420-1425
Authors:
PAGANI O
SESSA C
MARTINELLI G
CERNY T
DEJONG J
GOLDHIRSCH A
ZIMATORE M
CAVALLI F
Citation: O. Pagani et al., DOSE-FINDING STUDY OF PACLITAXEL AND CYCLOPHOSPHAMIDE IN ADVANCED BREAST-CANCER, Annals of oncology, 8(7), 1997, pp. 655-661
Authors:
JUDSON I
CERNY T
EPELBAUM R
DUNLOP D
SMYTH J
SCHAEFER B
ROELVINK M
KAPLAN S
HANAUSKE A
Citation: I. Judson et al., PHASE-II TRIAL OF THE ORAL PLATINUM COMPLEX JM216 IN NON-SMALL-CELL LUNG-CANCER - AN EORTC EARLY CLINICAL-STUDIES GROUP INVESTIGATION, Annals of oncology, 8(6), 1997, pp. 604-606
Authors:
BUSER K
JONCOURT F
ALTERMATT HJ
BACCHI M
OBERLI A
CERNY T
Citation: K. Buser et al., BREAST-CANCER - PRETREATMENT DRUG-RESISTANCE PARAMETERS (GSH-SYSTEM, ATASE, P-GLYCOPROTEIN) IN TUMOR-TISSUE AND THEIR CORRELATION WITH CLINICAL AND PROGNOSTIC CHARACTERISTICS, Annals of oncology, 8(4), 1997, pp. 335-341
Authors:
LOHRI A
VANHILLE B
BACCHI M
FOPP M
JONCOURT F
REUTER J
CERNY T
FEY MF
HERRMANN R
Citation: A. Lohri et al., 5 PUTATIVE DRUG-RESISTANCE PARAMETERS (MDR1 P-GLYCOPROTEIN, MDR-ASSOCIATED PROTEIN, GLUTATHIONE-S-TRANSFERASE, BCL-2 AND TOPOISOMERASE II-ALPHA) IN 57 NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIAS/, European journal of haematology, 59(4), 1997, pp. 206-215
Authors:
SESSA C
PAGANI O
MARTINELLI G
CERNY T
DEJONG J
GOLDHIRSCH A
ZIMATORE M
CAVALLI F
Citation: C. Sessa et al., DOSE-FINDING STUDY OF PACLITAXEL AND CYCLOPHOSPHAMIDE IN WOMEN WITH ADVANCED BREAST-CANCER, Seminars in oncology, 24(5), 1997, pp. 52-57
Authors:
BETTICHER DC
SCHMITZ SFH
RATSCHILLER D
VONROHR A
EGGER T
PUGIN P
STALDER M
HESS U
FEY MF
CERNY T
Citation: Dc. Betticher et al., CLADRIBINE (2-CDA) GIVEN AS SUBCUTANEOUS BOLUS INJECTIONS IS ACTIVE IN PRETREATED WALDENSTROMS MACROGLOBULINEMIA, British Journal of Haematology, 99(2), 1997, pp. 358-363
Authors:
SIEBER M
RUEFFER U
TESCH H
LIEBERZ D
PAULUS U
BROSTEANU O
LOEFFLER M
PFREUNDSCHUH M
LATHAN B
DUHMKE E
GEORGII A
HILLER E
KOCH P
DOLKEN G
CERNY T
CARTONI C
MANDELLI F
DIEHL V
Citation: M. Sieber et al., RAPIDLY ALTERNATING COPP PLUS ABV PLUS IMEP (CAI) IS EQUALLY EFFECTIVE AS ALTERNATING COPP PLUS ABVD (CA) FOR HODGKINS-DISEASE - FINAL RESULTS OF 2 RANDOMIZED TRIALS FOR INTERMEDIATE (HD5 PROTOCOL) AND ADVANCED (HD6 PROTOCOL) STAGES, Blood, 90(10), 1997, pp. 2605-2605
Authors:
BETTICHER DC
ZUCCA E
VONROHR A
EGGER T
RADFORD JA
AMBROSETTI A
BURKI K
RUFENER B
SCHMITZ SFH
CERNY T
Citation: Dc. Betticher et al., 2-CHLORODEOXYADENOSINE (2-CDA) THERAPY IN PREVIOUSLY UNTREATED PATIENTS WITH FOLLICULAR STAGE III-IV NON-HODGKINS-LYMPHOMA, Annals of oncology, 7(8), 1996, pp. 793-799
Authors:
AESCHLIMANN C
CERNY T
KUPFER A
Citation: C. Aeschlimann et al., INHIBITION OF (MONO)AMINE OXIDASE ACTIVITY AND PREVENTION OF IFOSFAMIDE ENCEPHALOPATHY BY METHYLENE-BLUE, Drug metabolism and disposition, 24(12), 1996, pp. 1336-1339
Authors:
KUPFER A
AESCHLIMANN C
CERNY T
Citation: A. Kupfer et al., METHYLENE-BLUE AND THE NEUROTOXIC MECHANISMS OF IFOSFAMIDE ENCEPHALOPATHY, European Journal of Clinical Pharmacology, 50(4), 1996, pp. 249-252
Authors:
BETTICHER DC
HEIGHWAY J
HASLETON PS
ALTERMATT HJ
RYDER WDJ
CERNY T
THATCHER N
Citation: Dc. Betticher et al., PROGNOSTIC-SIGNIFICANCE OF CCND1 (CYCLIN D1) OVEREXPRESSION IN PRIMARY RESECTED NON-SMALL-CELL LUNG-CANCER, British Journal of Cancer, 73(3), 1996, pp. 294-300
Authors:
JONCOURT F
OBERLISCHRAMMLI AE
STADLER M
BUSER K
FRANSCINI L
FEY MF
CERNY T
Citation: F. Joncourt et al., PATTERNS OF DRUG-RESISTANCE PARAMETERS IN ADULT LEUKEMIA, Leukemia & lymphoma, 17(1-2), 1995, pp. 101-109
Authors:
JOSS RA
BACCHI M
HURNY C
BERNHARD J
CERNY T
MARTINELLI G
LEYVRAZ S
SENN HJ
STAHEL R
SIEGENTHALER P
LUDWIG C
ALBERTO P
Citation: Ra. Joss et al., EARLY VERSUS LATE ALTERNATING CHEMOTHERAPY IN SMALL-CELL LUNG-CANCER, Annals of oncology, 6(2), 1995, pp. 157-166
Authors:
JOSS RA
ALBERTO P
HURNY C
BACCHI M
LEYVRAZ S
THURLIMANN B
CERNY T
MARTINELLI G
STAHEL R
LUDWIG C
Citation: Ra. Joss et al., QUALITY VERSUS QUANTITY OF LIFE IN THE TREATMENT OF PATIENTS WITH ADVANCED SMALL-CELL LUNG-CANCER - A RANDOMIZED PHASE-III COMPARISON OF WEEKLY CARBOPLATIN AND TENIPOSIDE VERSUS CISPLATIN, ADRIAMYCIN, ETOPOSIDE ALTERNATING WITH CYCLOPHOSPHAMIDE, METHOTREXATE, VINCRISTINE AND LOMUSTINE, Annals of oncology, 6(1), 1995, pp. 41-48
Authors:
SESSA C
ZUCCHETTI M
CERNY T
PAGANI O
CAVALLI F
DEFUSCO M
DEJONG J
GENTILI D
MCDANIEL C
PRINS C
SCHACTER I
WINOGRAD B
DINCALCI M
Citation: C. Sessa et al., PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF ORAL ETOPOSIDE PHOSPHATE, Journal of clinical oncology, 13(1), 1995, pp. 200-209